149 related articles for article (PubMed ID: 26969332)
1. Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort.
Wang HI; Smith A; Aas E; Roman E; Crouch S; Burton C; Patmore R
Eur J Health Econ; 2017 Mar; 18(2):255-267. PubMed ID: 26969332
[TBL] [Abstract][Full Text] [Related]
2. A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population-Based Observational Data.
Wang HI; Roman E; Crouch S; Aas E; Burton C; Patmore R; Smith A
Value Health; 2018 Oct; 21(10):1176-1185. PubMed ID: 30314618
[TBL] [Abstract][Full Text] [Related]
3. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
4. Microcosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi.
Painschab MS; Kohler RE; Kasonkanji E; Zuze T; Kaimila B; Nyasosela R; Nyirenda R; Krysiak R; Gopal S
J Glob Oncol; 2019 Jul; 5():1-10. PubMed ID: 31322992
[TBL] [Abstract][Full Text] [Related]
5. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
6. Cost burden of diffuse large B-cell lymphoma.
Harkins RA; Patel SP; Flowers CR
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):645-661. PubMed ID: 31623476
[No Abstract] [Full Text] [Related]
7. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.
Mounié M; Costa N; Conte C; Petiot D; Fabre D; Despas F; Lapeyre-Mestre M; Laurent G; Savy N; Molinier L
J Med Econ; 2020 Mar; 23(3):235-242. PubMed ID: 31876205
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
9. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
Costa S; Scott DW; Steidl C; Peacock SJ; Regier DA
Curr Oncol; 2019 Apr; 26(2):108-113. PubMed ID: 31043812
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA.
Morrison VA; Bell JA; Hamilton L; Ogbonnaya A; Shih HC; Hennenfent K; Eaddy M; Shou Y; Galaznik A
Future Oncol; 2018 Oct; 14(25):2627-2642. PubMed ID: 29911900
[TBL] [Abstract][Full Text] [Related]
11. Long-term medical costs and life expectancy of acute myeloid leukemia: a probabilistic decision model.
Wang HI; Aas E; Howell D; Roman E; Patmore R; Jack A; Smith A
Value Health; 2014 Mar; 17(2):205-14. PubMed ID: 24636378
[TBL] [Abstract][Full Text] [Related]
12. Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center.
Lee RC; Zou D; Demetrick DJ; Difrancesco LM; Fassbender K; Stewart D
Value Health; 2008; 11(2):221-30. PubMed ID: 18380634
[TBL] [Abstract][Full Text] [Related]
13. The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network.
Kane E; Painter D; Smith A; Crouch S; Oliver S; Patmore R; Roman E
Cancer Epidemiol; 2019 Apr; 59():236-243. PubMed ID: 30844679
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada.
Johnston KM; Marra CA; Connors JM; Najafzadeh M; Sehn L; Peacock SJ
Value Health; 2010; 13(6):703-11. PubMed ID: 20561333
[TBL] [Abstract][Full Text] [Related]
16. Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.
Khor S; Beca J; Krahn M; Hodgson D; Lee L; Crump M; Bremner KE; Luo J; Mamdani M; Bell CM; Sawka C; Gavura S; Sullivan T; Trudeau M; Peacock S; Hoch JS
BMC Cancer; 2014 Aug; 14():586. PubMed ID: 25117912
[TBL] [Abstract][Full Text] [Related]
17. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
18. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
19. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
Tsutsué S; Tobinai K; Yi J; Crawford B
PLoS One; 2020; 15(8):e0237509. PubMed ID: 32810157
[TBL] [Abstract][Full Text] [Related]
20. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
